TipRanks
Idorsia Ltd (CH:IDIA)
:IDIA
Switzerland Market
IDIA
Idorsia Ltd
RESEARCH TOOLSreports
Want to see CH:IDIA full AI Analyst Report?

Idorsia Ltd (IDIA) Stock News & Sentiment

16 Followers
Premium
Ratings
Idorsia Maintained at Buy as New Phase 3 Data Strengthen Aprocitentan Profile; 12‑Month Price Target Reaffirmed at CHF5
4M ago
Premium
Ratings
Buy Rating Reaffirmed on Daridorexant Growth Prospects; 12‑Month Price Target Maintained at $5
5M ago
Idorsia: Positive Pediatric Daridorexant Data and Neurodevelopmental Expansion Drive Buy Rating and CHF5 Target
Premium
Ratings
Idorsia: Positive Pediatric Daridorexant Data and Neurodevelopmental Expansion Drive Buy Rating and CHF5 Target
6M ago
Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
Premium
Ratings
Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
7M ago
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
Premium
Ratings
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
7M ago
Idorsia Earnings Call Signals Turnaround, Risks Linger
Premium
Company Announcements
Idorsia Earnings Call Signals Turnaround, Risks Linger
7M ago
Idorsia: FDA-Aligned Phase 3 Pathway and Broad Fabry Disease Positioning Support Buy Rating and CHF6 Target
Premium
Ratings
Idorsia: FDA-Aligned Phase 3 Pathway and Broad Fabry Disease Positioning Support Buy Rating and CHF6 Target
8M ago
More CH:IDIA News >

IDIA News on the Web

Idorsia Ltd (IDIA) Gets a Hold from Deutsche Bank
TipRanks News
Neutral
Buy Rating Reaffirmed on Daridorexant Growth Prospects; 12‑Month Price Target Maintained at $5
TipRanks News
Bullish
Idorsia Ltd (IDIA) Receives a Rating Update from a Top Analyst
TipRanks News
Bullish
Idorsia: Positive Pediatric Daridorexant Data and Neurodevelopmental Expansion Drive Buy Rating and CHF5 Target
TipRanks News
Neutral
Idorsia's Daridorexant Shows Positive Phase 2 Results In Paediatric Insomnia; Stock Up
rttnews
Bullish
Idorsia: Leadership Reset and Pipeline Expansion Underpin Buy Rating and CHF5 Price Target
TipRanks News
Bullish
Idorsia: Expanding QUVIVIQ Footprint and Aprocitentan Upside Support Buy Rating Despite Lowered Target
TipRanks News
Bullish
Idorsia price target lowered to CHF 5 from CHF 6 at H.C. Wainwright
TipRanks News
Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0.25 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CH:IDIA’s Media Buzz Sentiment?
Currently, no data Available
What is CH:IDIA’s weekly average amount of articles?
In an average week, 0.25 articles about CH:IDIA are published.
    What is CH:IDIA’s News Sentiment?
    Currently, no data Available
    General Stocks that are Trending in the News
    RPDRapid7
    TERATera Yatirim Menkul Degerler AS
    R2PD34Rapid7 Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.083333 Sh
    T2TD34Trade Desk, Inc. Shs A Unsponsored Brazilian Depositary Receipt Repr 0.01 Sh A
    T1AM34Atlassian Corp Shs A Unsponsored Brazilian Depository Receipt Repr 0.05 Sh A
    Showing the stocks with the most bullish news sentiment over the past week